Equities
Health CarePharmaceuticals and Biotechnology
  • Price (DKK)198.70
  • Today's Change6.25 / 3.25%
  • Shares traded280.83k
  • 1 Year change+30.47%
  • Beta1.7114
Data delayed at least 15 minutes, as of Nov 22 2024 15:23 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of DKK
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments1,8672,8453,717
Total Receivables, Net1,827535448
Total Inventory1,644919480
Prepaid expenses19154109
Other current assets, total46320.19
Total current assets5,4034,4854,754
Property, plant & equipment, net2,4531,7511,489
Goodwill, net------
Intangibles, net6,4825,9435,804
Long term investments------
Note receivable - long term------
Other long term assets115.094.78
Total assets14,35312,39112,089
LIABILITIES
Accounts payable954606264
Accrued expenses420228126
Notes payable/short-term debt000
Current portion long-term debt/capital leases471,1301,473
Other current liabilities, total1,36732346
Total current liabilities2,7882,2871,909
Total long term debt99632,646
Total debt1451,1934,119
Deferred income tax29----
Minority interest------
Other liabilities, total1,0982,891161
Total liabilities4,0135,2414,715
SHAREHOLDERS EQUITY
Common stock781707705
Additional paid-in capital------
Retained earnings (accumulated deficit)9,5046,4366,703
Treasury stock - common(1.54)(1.46)(1.11)
Unrealized gain (loss)4632(1.35)
Other equity, total11(24)(31)
Total equity10,3407,1507,375
Total liabilities & shareholders' equity14,35312,39112,089
Total common shares outstanding787170
Treasury shares - common primary issue0.040.070.03
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.